RNA modifications in hematological malignancies

• Published in: International journal of hematology Vol. 117; no. 6; pp. 807 - 820
• Main Authors: Jin, Zhen, MacPherson, Kyle, Liu, Zongmin, Vu, Ly P.
• Format: Journal Article
• Language: English
• Published: Singapore Springer Nature Singapore 01.06.2023; Springer Nature B.V
• Subjects: Cancer; Cell Differentiation; Cell fate; Cell proliferation; Gene expression; Hematologic Neoplasms - genetics; Hematologic Neoplasms - therapy; Hematological diseases; Hematology; Humans; Leukemia; Leukemia - genetics; Leukemia - therapy; Leukemogenesis; Malignancy; Medicine; Medicine & Public Health; N6-methyladenosine; Oncology; Pathogenesis; Progress in Hematology; Regulatory mechanisms (biology); Ribonucleic acid; RNA; RNA modification; RNA, Messenger - genetics; Tumorigenesis; AML; ALL; RNA modification profiling; RNA modifications; RNA methylation; Hematological malignancies
• ISSN: 0925-5710; 1865-3774
• DOI: 10.1007/s12185-023-03576-0

RNA modifications play an important role in various cancers including blood cancers by controlling gene expression programs critical for survival, proliferation and differentiation of cancer cells. While hundreds of RNA modifications have been identified, many have not been functionally characterized. With development of enabling technologies to identify and map RNA modifications, tremendous advancement has been made in our understanding of the biological functions of these molecular markers in diverse cellular contexts. In the last 5 years, N 6 -methyladenosine (m 6 A), the most prevalent internal mRNA modification, has been extensively implicated in many facets of leukemogenesis. Other types of RNA modifications are also involved in the regulation of cell fate decisions and tumorigenesis. Here, we summarize existing knowledge and recent discoveries regarding the role of RNA modifications in leukemia. We choose to highlight cutting-edge techniques to characterize and profile RNA modifications while discussing critical functions of key modifiers and regulatory mechanisms in the pathogenesis of hematological malignancies and touch on therapeutic strategies targeting RNA modifications. These important advancements in the field will continue to foster a strong foundation for the development of innovative treatments for hematological malignancies.